Literature DB >> 31292783

Bedside Measures of Frailty and Cognitive Function Correlate with Sarcopenia in Patients with Cirrhosis.

Elliot B Tapper1,2, Brian Derstine3, Jad Baki4, Grace L Su5,6.   

Abstract

BACKGROUND: Frailty and sarcopenia are associated with mortality and poor outcomes among patients with cirrhosis. Frailty is multifactorial but due in part to sarcopenia and cognitive dysfunction. Data are limited regarding the correlation of bedside frailty and cognitive function measures with sarcopenia. AIMS: To evaluate the correlations between frailty measures and muscle indices from computed tomography (CT).
METHODS: We prospectively enrolled 106 patients with clinically compensated cirrhosis (and no prior hepatic encephalopathy). All patients underwent CT scan and cognitive testing (via inhibitory control test, ICT), and were subject to hand grip, 30-s chair stands, mid-arm muscle area (MAMA), and a four-question algorithm based on the Sickness Impact Profile (SIP) predictive of minimal HE. We evaluated Spearman correlations between all measures as well as the sensitivity and specificity of each measure for falls.
RESULTS: In total, 106 (35.3%) patients (55 men) had CT scans to measure skeletal muscle area and quality. Hand grip correlated strongly with skeletal muscle area (correlation coefficient 0.64, p < 0.001) and mildly with ICT performance (0.34, p = 0.002). However, for women, the strongest correlation with hand grip was ICT performance (0.60, p < 0.001). Chair stand performance correlated best with SIP (correlation coefficient - 0.35, p < 0.001). MAMA was not correlated with CT-based muscle indices among women but was for men. Poor chair stand performance (< 10/30-s) had a sensitivity/specificity for falls of 73%/54%; low muscle radiation attenuation (density) was 40%/80% sensitive/specific.
CONCLUSION: Bedside measures of physical function, muscle bulk, and cognitive performance are correlated with CT-based muscle measures. Bedside measures of frailty may provide an advantage over sarcopenia for outcome assessment that should be confirmed prospectively.

Entities:  

Keywords:  Falls; Hepatic encephalopathy; Liver disease; Portal hypertension

Mesh:

Year:  2019        PMID: 31292783     DOI: 10.1007/s10620-019-05713-4

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  1 in total

1.  Frailty in liver transplantation: An expert opinion statement from the American Society of Transplantation Liver and Intestinal Community of Practice.

Authors:  Jennifer C Lai; Christopher J Sonnenday; Elliot B Tapper; Andres Duarte-Rojo; Michael A Dunn; William Bernal; Elizabeth J Carey; Srinivasan Dasarathy; Binita M Kamath; Matthew R Kappus; Aldo J Montano-Loza; Shunji Nagai; Puneeta Tandon
Journal:  Am J Transplant       Date:  2019-05-08       Impact factor: 8.086

  1 in total
  16 in total

1.  Cognitive Function, Sarcopenia, and Inflammation Are Strongly Associated with Frailty: A Framingham Cohort Study.

Authors:  Manaav Mehta; Jeremy Louissaint; Neal S Parikh; Michelle T Long; Elliot B Tapper
Journal:  Am J Med       Date:  2021-08-28       Impact factor: 4.965

2.  A Comparison of Different Frailty Scores and Impact of Frailty on Outcome in Patients With Cirrhosis.

Authors:  Surender Singh; Sunil Taneja; Puneeta Tandon; Akash Bansal; Ujjwal Gorsi; Akash Roy; Arka De; Nipun Verma; Madhumita Premkumar; Ajay Duseja; Radha K Dhiman; Virendra Singh
Journal:  J Clin Exp Hepatol       Date:  2021-07-21

3.  Assessment of frailty in cirrhosis using bedside measures and its correlation with Child-Turcotte-Pugh, MELD & MELD-Na Scores.

Authors:  Bader Faiyaz Zuberi; Tazeen Rasheed; Faiza Sadaqat Ali; Nimrah Bader; Rabia Sadaf
Journal:  Pak J Med Sci       Date:  2022 May-Jun       Impact factor: 2.340

4.  Inpatient Frailty Assessment Is Feasible and Predicts Nonhome Discharge and Mortality in Decompensated Cirrhosis.

Authors:  Marina Serper; Sunny Y Tao; Dorothea S Kent; Patrik Garren; Alexander E Burdzy; Jennifer C Lai; Amir Gougol; Pamela M Bloomer; K Rajender Reddy; Michael A Dunn; Andres Duarte-Rojo
Journal:  Liver Transpl       Date:  2021-08-01       Impact factor: 5.799

5.  European Working Group on Sarcopenia in Older People (EWGSOP2) Criteria With Population-Based Skeletal Muscle Index Best Predicts Mortality in Asians With Cirrhosis.

Authors:  Abhinav Anand; Srikant Mohta; Samagra Agarwal; Sanchit Sharma; Srikanth Gopi; Deepak Gunjan; Kumble S Madhusudhan; Namrata Singh; Anoop Saraya
Journal:  J Clin Exp Hepatol       Date:  2021-04-08

6.  Falls are common, morbid, and predictable in patients with cirrhosis.

Authors:  Elliot B Tapper; Samantha Nikirk; Neehar D Parikh; Lilli Zhao
Journal:  J Hepatol       Date:  2021-04-19       Impact factor: 30.083

Review 7.  Sarcopenia and cognitive impairment in liver cirrhosis: A viewpoint on the clinical impact of minimal hepatic encephalopathy.

Authors:  Silvia Nardelli; Stefania Gioia; Jessica Faccioli; Oliviero Riggio; Lorenzo Ridola
Journal:  World J Gastroenterol       Date:  2019-09-21       Impact factor: 5.742

8.  Malnutrition, Frailty, and Sarcopenia in Patients With Cirrhosis: 2021 Practice Guidance by the American Association for the Study of Liver Diseases.

Authors:  Jennifer C Lai; Puneeta Tandon; William Bernal; Elliot B Tapper; Udeme Ekong; Srinivasan Dasarathy; Elizabeth J Carey
Journal:  Hepatology       Date:  2021-09       Impact factor: 17.298

9.  Incidence and Bedside Predictors of the First Episode of Overt Hepatic Encephalopathy in Patients With Cirrhosis.

Authors:  Elliot B Tapper; Lilli Zhao; Samantha Nikirk; Jad Baki; Neehar D Parikh; Anna S Lok; Akbar K Waljee
Journal:  Am J Gastroenterol       Date:  2020-12       Impact factor: 12.045

10.  Validation of the Clinical Frailty Scale for the Prediction of Mortality in Patients With Liver Cirrhosis.

Authors:  Wolfgang M Kremer; Michael Nagel; Michael Reuter; Max Hilscher; Maurice Michel; Leonard Kaps; Joachim Labenz; Peter R Galle; Martin F Sprinzl; Marcus-Alexander Wörns; Christian Labenz
Journal:  Clin Transl Gastroenterol       Date:  2020-07       Impact factor: 4.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.